Ballentine Partners, LLC Exelixis, Inc. Transaction History

Ballentine Partners, LLC

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 19, 2023	BUY	$19.04 - $22.74 $262,523 - $313,539	13,788 New	13,788 $301,000
Q1 2023 Apr 27, 2023	BUY	$16.3 - $19.41 $3,439 - $4,095	211 Added 1.7%	12,615 $244,000
Q4 2022 Jan 27, 2023	BUY	$14.96 - $17.39 $5,086 - $5,912	340 Added 2.82%	12,404 $0
Q3 2022 Oct 26, 2022	SELL	$15.68 - $22.27 $1,317 - $1,870	-84 Reduced 0.69%	12,064 $189,000
Q2 2022 Aug 09, 2022	SELL	$17.44 - $23.16 $105,128 - $139,608	-6,028 Reduced 33.16%	12,148 $253,000
Q1 2022 May 05, 2022	BUY	$17.03 - $22.67 $2,946 - $3,921	173 Added 0.96%	18,176 $412,000
Q3 2021 Oct 27, 2021	SELL	$16.3 - $21.14 $3,390 - $4,397	-208 Reduced 1.14%	18,003 $381,000
Q2 2021 Aug 12, 2021	SELL	$17.95 - $25.56 $4,900 - $6,977	-273 Reduced 1.48%	18,211 $332,000
Q1 2021 May 11, 2021	BUY	$20.53 - $25.22 $6,384 - $7,843	311 Added 1.71%	18,484 $418,000
Q4 2020 Jan 25, 2021	BUY	$18.39 - $24.8 $3,126 - $4,216	170 Added 0.94%	18,173 $365,000
Q2 2020 Jul 31, 2020	SELL	$16.46 - $27.42 $459,546 - $765,538	-27,919 Reduced 60.8%	18,003 $428,000
Q1 2020 Apr 23, 2020	BUY	$14.46 - $21.8 $404,822 - $610,312	27,996 Added 156.18%	45,922 $791,000
Q4 2019 Jan 22, 2020	BUY	$15.15 - $18.89 $271,578 - $338,622	17,926 New	17,926 $316,000
Q4 2018 Feb 04, 2019	SELL	$13.65 - $21.8 $136,500 - $218,000	-10,000 Closed	0 $0
Q4 2017 Feb 02, 2018	SELL	$24.23 - $30.93 $12,090 - $15,434	-499 Reduced 4.75%	10,000 $304,000
Q3 2017 Nov 06, 2017	BUY	$23.35 - $29.24 $245,151 - $306,990	10,499	10,499 $254,000

507

243M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.7B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Ballentine Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Ballentine Partners, LLC with notifications on news.